Mara Goldstein

Analyst: CytomX Therapeutics Validated By AbbVie Decision

Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial

Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside

Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial

Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside

Progenics Shares Could Double, According To Cantor

Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone

Progenics Shares Could Double, According To Cantor

Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone

Biotech Winners And Losers From ASH Conference

Ignyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4%